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Abstract
Background: Global assessment allows patients to assess improvement in multiple irritable bowel syndrome (IBS)
symptoms. However, it was deemed important to assess “clinically meaningful improvements, focusing on the
patient’s chief complaint and the severity of major IBS symptoms” in addition to global assessment to show how
ramosetron is effective for individual IBS symptoms. This is a pilot study to explore clinical endpoints focusing on
the chief complaint of patients with IBS with diarrhea (IBS-D).
Methods: The same database was used in a previously reported post-marketing phase IV, randomized placebo-
controlled pilot trial in male patients with IBS-D. The hypothesis is completely different from that of the other study.
Patients with IBS-D diagnosed according to Rome III criteria were given either 5 μg of ramosetron (n = 47) or
placebo (n = 51) once daily for 12 weeks after a one-week baseline period. To explore and examine endpoints that
allow evaluation of “clinically meaningful improvements focusing on the patient’s chief complaint,” the chief
complaint and its relief by this study drug were assessed in this exploratory study.
Results: Rates of patients with abdominal pain/discomfort, stool form and stool frequency which patients had as a
chief complaint before administration were 34.0, 19.1 and 25.5%, respectively, in the ramosetron 5 μg group and 42.
0, 18.0, and 20.0% in the placebo group. Responder rates for improvement in symptoms of the chief complaint that
patients had before administration were 53.2% in the ramosetron 5 μg group and 42.0% in the placebo group at
the last point. The greatest symptomatic improvement in the chief complaint in the ramosetron 5 μg group
compared to the placebo group was shown with respect to stool consistency. Bristol Stool Form Scale (BSFS) scores
were significantly lower in the ramosetron group than in the placebo group (4.36 ± 1.195 vs 4.85 ± 0.890 at the last
point, P = 0.027) throughout the treatment period, except at week 6.
Conclusions: Ramosetron acted most effectively on stool consistency. Improvement in stool consistency is
considered to be a clinically meaningful endpoint in showing how ramosetron was effective for individual IBS
symptoms. (Clinicaltrials.gov ID: NCT00918411. Registered 9 June 2009).
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Background
Irritable bowel syndrome (IBS) is a functional disease
characterized by prolonged persistence or recurrence of
abnormal bowel habits and abdominal pain and discom-
fort without organic diseases or biochemical abnormal-
ities [1]. IBS is not a life-threatening disease, but has
been shown to limit the activity of patients and to nega-
tively impact social functioning, with substantial eco-
nomic loss [2]. It is also reported that IBS can severely
compromise the patient’s quality of life (QOL), even to a
greater extent than in patients with end-stage renal dis-
ease or patients with diabetes [3]. Surveys conducted
outside Japan have reported that the estimated preva-
lence of IBS in the general population is from 5 to 20%,
with about 200 new patients per 100,000 population per
year [4, 5]. In Japan, a large population-based internet
survey using the Rome III criteria by Kanazawa et al. re-
vealed that about 16.5% of the survey population met
the Rome III criteria for IBS [6]. A web-based survey by
Miwa that used Rome III showed that 13% of the re-
spondents had IBS [7].
A variety of factors are considered to be involved in
the etiology of IBS, including abnormal gastrointestinal
(GI) motility, visceral hypersensitivity, abnormal brain–
gut interactions, GI infection, and sociopsychological
strain [8]. Stress-related disturbance of brain–gut inter-
actions is a particularly important factor in functional
gastrointestinal disorders including IBS [9]. IBS patients
reported significantly more stress than controls without
bowel dysfunction and the slope of the regression equa-
tion relating bowel symptoms to stress was significantly
steeper for the IBS group [10]. Stress is therefore consid-
ered to induce abnormal GI motility via efferent nerves,
which in turn worsen the stress response by stimulating
afferent nerves, resulting visceral hypersensitivity. This
vicious cycle is thought to cause persistence of bowel
symptoms. Patients with IBS with diarrhea (IBS-D) show
exaggerated colonic motility in response to colonic
distention [11] and secretion of 5-hydroxytryptamine (5-
HT, serotonin) [12].
Ramosetron, a potent and selective 5-hydroxytryptamine
3 (5-HT3) receptor antagonist [13–16], was developed
and has been approved at a dosage of “ramosetron
5 μg for IBS-D in male patients” since July, 2008 in
Japan [17, 18], followed by a supplemental indication
and dosage of “ramosetron 2.5 μg for female patients”
in May, 2015 [19–21]. In rats, ramosetron clearly re-
duces stress-induced diarrhea and defecation caused by
corticotrophin-releasing hormone [14, 15]. In addition,
ramosetron increases the threshold of abdominal pain
responses induced by colonic distension in rats [22].
Thus, ramosetron is expected to improve IBS symp-
toms via reducing the vicious cycle for stress-related
disturbance of brain–gut interactions.
The choice of primary endpoint for a clinical trial is
one of the most important determinants of the ability of
a clinical trial to demonstrate the efficacy of therapeutic
agents. The Committee on Functional Bowel Disorders
and Functional Abdominal Pain, an international work-
ing group for the establishment of diagnostic criteria for
functional gastrointestinal tract disturbances including
IBS, discussed primary variables in clinical studies. It
was concluded that, since IBS is a syndrome, instead of
evaluating individual symptoms the improvement of
overall symptoms of the syndrome should be assessed
and subjects should evaluate the effects of therapeutics
because improvement of subjective symptoms is clinic-
ally important for IBS [23]. Consequently, the global as-
sessment of relief of overall IBS symptoms was chosen
to be the primary variable for previous clinical studies of
ramosetron [17, 18], and its efficacy was demonstrated.
Global assessment allows patients to assess improvement
of multiple IBS symptoms, however, global assessment
cannot show how ramosetron is effective for individual
IBS symptoms. Therefore, it was deemed beneficial to
assess “clinically meaningful improvements, focusing on
the patient’s chief complaint and the severity of major
IBS symptoms” in addition to the global assessment.
This study was conducted as a pilot study to explore
and examine those variables. Results that focus on the
severity of major IBS symptoms are contained in a previ-
ous report [24]. We thus used the same database as the
previous report, but the hypothesis was completely
different from that of the previous study. This report
concentrates on improvement of the patient’s chief com-
plaint in a clinical study of ramosetron.
Methods
Patient population
The patients were the same as in our previous report
[24]. In brief, this study was conducted from June 2009
to December 2009 at 25 Japanese centers that have de-
partments of gastroenterology. Almost all of the sites
were primary care. Male outpatients aged 20–64 years
were diagnosed with IBS-D based on the Rome III cri-
teria. The study protocol was designed in accordance
with the Declaration of Helsinki and was approved by
the institutional review board at each site. All patients
provided written informed consent prior to participating
in study-related procedures.
Patients satisfying the inclusion and exclusion criteria
were enrolled in this study. Based on a medical interview
conducted by the attending physician before provisional
registration, patients were excluded if any of the follow-
ing were evident: a history of resection of the stomach,
small intestine, or large intestine (excluding appendicitis
or resection of benign polyps); history or current evi-
dence of inflammatory bowel disease; history or current
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evidence of ischemic colitis, concurrent infectious enter-
itis, hyperthyroidism, hypothyroidism, or other diseases
that may affect gastrointestinal transit or colonic func-
tion; history or current evidence of abuse of drugs or al-
cohol within the previous year; malignant tumors;
current evidence of severe depression or a severe anxiety
disorder that could potentially affect the evaluation of
study drug efficacy; concurrent serious cardiovascular,
respiratory, renal, hepatic, gastrointestinal (excluding
IBS), hematological, or neurological/psychiatric diseases;
or a history of drug allergies. Other inclusion and exclu-
sion criteria can be found in our previous report [24].
Study design
This randomized, placebo-controlled, pilot clinical trial
comprised a provisional registration period, a one-week
baseline period, and a 12-week treatment period, similar
to previous studies [17, 18]. Following the baseline
period, eligible patients were randomly assigned to 12-
week oral treatment with placebo or ramosetron hydro-
chloride 5 μg once daily before breakfast. Visits were
scheduled at Weeks 2, 4, 8, and 12 (or at discontinu-
ation) to assess treatment efficacy, drug compliance, and
occurrence of adverse events. Randomization was per-
formed in a 1:1 ratio using a block size of four based on
a randomization list developed by a third-party contract
research organization. Placebo tablets were externally
distinguishable from ramosetron hydrochloride tablets,
however, they were indistinguishable when packaged in
press through pack sheets. All patients, investigators,
and sponsors were blinded until all observations and
evaluations were completed, statistical analysis plans
were finalized, and all data had been locked. All authors
had access to the study data and reviewed and approved
the final manuscript.
Data collection
Patients recorded Bristol Stool Form Scale (BSFS) [25]
for every bowel movement throughout the study period
in their diaries. They scored the severity of all abdominal
pain/discomfort they had experienced on a five-point or-
dinate (numerical rating) scale and their continuous time
at baseline, from week 1 to week 4, and at weeks 8 and
12. Every seven days during the treatment period, pa-
tients also graded summarized IBS symptoms compared
with the baseline period on a five-point ordinate scale as
follows: relief from overall IBS symptoms and abdominal
pain/discomfort (0, completely relieved; 1, considerably
relieved; 2, somewhat relieved; 3, unchanged; and 4,
worsened) and improvement in abnormal bowel habits
(0, nearly normalized; 1, considerably relieved; 2, some-
what relieved; 3, unchanged; and 4, worsened).
Symptoms related to the chief complaint were clarified
by an investigator at an interview. The investigator
scored the most bothersome IBS symptoms the patient
had (nothing, abdominal pain/discomfort, stool form,
stool frequency, urgency, feeling of incomplete evacu-
ation, and others) as symptoms of the chief complaint at
the week 0, 4, 8 and 12 (or at discontinuation) visits.
The investigator also scored any improvement in symp-
toms of the chief complaint the patients had before ad-
ministration compared to the baseline period on a five-
point ordinate scale (0, completely relieved; 1, consider-
ably relieved; 2, somewhat relieved; 3, unchanged; and 4,
worsened) at the week 4, 8 and 12 (or at discontinu-
ation) visits.
Efficacy and safety endpoints
To explore and examine variables that allow evaluation
of “clinically significant improvements, focusing on the
patient’s chief complaint,” the chief complaint and its
relief by the study drug were assessed in this explora-
tory study. As an ad hoc analysis, patients with scores
of 0 (completely relieved) or 1 (considerably relieved)
at each evaluation point were defined as responders,
with relief of their chief complaint. Patients with miss-
ing data were regarded as non-responders. Improve-
ment in stool consistency was also analyzed for the
patients with baseline BSFS scores over five, in an ad
hoc manner. Patients with weekly mean BSFS scores of
3 to 5 during one week of the treatment period and a
decrease of one or more points in mean BSFS scores
from the baseline period were defined as weekly re-
sponders. Patients who were weekly responders for at
least two of four weeks in a month were considered
monthly responders. If more than two daily scores
were missing during any week of the study period, the
mean score for that week was defined as missing. Pa-
tients with missing mean BSFS scores were regarded
as weekly non-responders.
Statistical analysis
Sample sizes of 60 patients or more (30 patients/group
or more) were set based on the feasibility of a post mar-
keting study to explore and examine endpoints rerated
to the patient’s chief complaint or IBS severity. Statistical
analysis was performed using SAS Drug Development
(ver. 3.4) and PC-SAS (ver. 8.2) (SAS Institute Inc., Cary,
NC, USA).
Efficacy analyses were performed on the full analysis
set (FAS), which was as complete as possible and as
close as possible to the intention-to-treat ideal of includ-
ing all randomized subjects. The FAS included all pa-
tients who received at least one dose of the study drug
during the treatment period and for whom at least one
endpoint could be evaluated. To determine the robust-
ness of the results, primary analyses were performed ac-
cording to the per-protocol set. Safety analyses were
Ida et al. BioPsychoSocial Medicine  (2017) 11:8 Page 3 of 10
performed for all patients who received at least one dose
of the study drug during the treatment period.
Improvement in symptoms of the chief complaint that
patients had before administration was scored at each
evaluation point. The treatment groups were compared
using the Wilcoxon rank sum test with a two-sided sig-
nificance level of 0.05.
A responder for improvement in symptoms of the
chief complaint was defined as a patient with score of 0
or 1 at each evaluation point, with the chi-square test
used for ad hoc analysis. BSFS was evaluated using the t-
test. Monthly responder rates for improvement in stool
consistency were analyzed in an ad hoc manner for pa-
tients with baseline BSFS scores over 5, using a chi-
square test.
There was no adjustment for multiplicity in this study.
Results
Overall study population
Written informed consent was provided by 115 patients.
Of these, 17 patients dropped out and 98 patients were
randomly allocated to the ramosetron 5 μg (n = 47) or
the placebo group (n = 51) [24]. Ultimately 44 patients in
the ramosetron group and 45 patients in the placebo
group completed the study. The reasons for discontinu-
ation are shown in the previous report. In this study,
one patient in the placebo group who discontinued after
randomization by withdrawing consent with no data
available was excluded from the FAS used in the efficacy
analyses. The decision to exclude this patient from the
FAS was taken before unblinding, according to the pre-
defined procedure stipulated in the study protocol.
All the demographic and baseline characteristics used
in this study are shown in the previous report [24] and
are similar among patients allocated to each group and
almost the same as in other ramosetron clinical studies
[17, 18]. Duration of disease was 111.5 ± 129.10 months
in the ramosetron 5 μg group and 103.9 ± 90.27 months
in the placebo group (P = 0.738).
Efficacy
Table 1 shows the symptoms of the chief complaint
that patients had before administration. Abdominal
pain/discomfort, stool form, and stool frequency were
key symptoms for the patients enrolled in this study.
The proportion of patients whose chief complaint was
abdominal pain/discomfort was 34.0% in the ramosetron
5 μg group and 42.0% in the placebo group. Regarding
stool form and stool frequency, key symptoms among
bowel habit abnormalities, the respective proportion of
patients was 19.1 and 25.5% in the ramosetron 5 μg group
and 18.0 and 20.0% in the placebo group.
Improvement in the symptoms of the chief complaint
that patients had before administration was assessed on
a five-point ordinate scale at every visit (Fig. 1a). Patients
with scores of 0 (completely relieved) or 1 (considerably
relieved) at each evaluation point were defined as re-
sponders (Fig. 1b. ad hoc analysis). Responder rates for
improvement in the symptoms of the chief complaint
that patients had before administration were 53.2% (95%
confidence interval [CI], 38.1–67.9 at the last point) in
the ramosetron 5 μg group and 42.0% (95% CI, 28.2–
56.8 at the last point, P = 0.368) in placebo. The differ-
ence between placebo and ramosetron was over 10% at
all evaluation points.
Figure 2 shows improvement in the symptoms of each
chief complaint that patients had before administration.
Regarding stool consistency, the number of patients who
had completely relieved or considerably relieved symp-
toms in the ramosetron 5 μg group increased in a time-
dependent manner. Almost all patients showed com-
pletely relieved (12.5%) or considerably relieved (75%)
symptoms in relation to stool consistency in the ramose-
tron 5 μg group at Week 12. The difference between
ramosetron and placebo was greatest with respect to
stool consistency. Improvement in the ramosetron 5 μg
group compared to placebo was also observed with re-
spect to stool frequency at all evaluation points. Among
patients who had abdominal pain/discomfort as a symp-
tom of their chief complaint before administration, pa-
tients in the ramosetron 5 μg group showed numerous
improvements at Weeks 4 and 8 compared to patients
in the placebo group with the same symptoms, however,
the difference between ramosetron and placebo was not
clear at Week 12 and at the last evaluation point.
BSFS scores were significantly lower in the ramosetron
5 μg group (4.36 ± 1.195 at the last point) than in the
placebo group (4.85 ± 0.890 at the last point, P = 0.027)
throughout the treatment period, except at week 6
(Fig. 3). No significant difference was observed between
the ramosetron 5 μg group and the placebo group
regarding changes in the severity of abdominal pain/
discomfort and stool frequency from baseline per
week (data not shown).
Table 1 Chief complaint that patients had before
administration of the study drug






None 0 (0.0%) 0 (0.0%)
Abdominal pain/discomfort 21 (42.0%) 16 (34.0%)
Stool form 9 (18.0%) 9 (19.1%)
Stool frequency 10 (20.0%) 12 (25.5%)
Urgency 6 (12.0%) 7 (14.9%)
Feelings of incomplete evacuation 4 (8.0%) 3 (6.4%)
Others 0 (0.0%) 0 (0.0%)
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Because stool form was considered to be the most ef-
fective symptom for demonstrating if ramosetron brought
about a clinically meaningful improvement, monthly re-
sponder rates for improvement in stool consistency were
analyzed ad hoc for patients with baseline BSFS scores
over 5 (Fig. 4). Responder rates for improvement in stool
consistency were 40.5% (95% CI, 25.6–56.7 at the last
point) in the ramosetron 5 μg group and 18.9% (95% CI,
8.0–35.2 at the last point, P = 0.067) in the placebo group.
The difference between placebo and ramosetron was over
19% at all evaluation points.
Improvement in the chief compliant that patients had
before administration was compared by responder/non-
responder for global assessment of relief of overall IBS
symptoms (Fig. 5). Regarding stool consistency, patients
who reported that they were completely relieved or con-
siderably relieved in the improvement of chief complaint
were more numerous in the responder group on global
assessment compared to the non-responder group (8/9,
88.9% vs 3/9, 33.3% at the last point). The same results
were observed for abdominal pain/discomfort (11/14,
78.6% vs 8/23, 34.8% at the last point) and stool fre-
quency (7/9, 77.8% vs 1/13, 7.7% at the last point).
Safety
The incidence of adverse events is shown in Table 2.
The incidence of “hard stool” was higher in the ramose-
tron 5 μg group (19.1%) than in the placebo group
(5.9%), which was considered to be caused by the
pharmacological action of ramosetron. Constipation was
only observed in the placebo group (3.9%). All hard stool
and constipation were assessed as drug-related adverse
events, except for one patient in placebo with hard stool.
All events including constipation and hard stool
a
b


















































































































Fig. 1 Improvement in symptoms of the chief complaint that patients had before administration of the study drug. a Improvement in symptoms
of the chief complaint that patients had before administration of the study drug. b Responder rate for improvement in symptoms of the chief
complaint that patients had before administration of the study drug. Height: responder rate (%). Error bar: 95% CI. P values were calculated using
the χ2-test
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observed in this study were mild and improved quickly.
There was no occurrence of ischemic colitis or serious
adverse events.
Discussion
Because IBS is a syndrome, most previous studies to de-
velop agents for IBS have used global assessments as
primary endpoints, as these allow patients to assess the
improvement of overall symptoms of IBS [17–21, 26, 27].
Individual symptoms of IBS were assessed as secondary
endpoints. The most bothersome IBS symptoms reported
in clinical trials of alosetron were abdominal pain and ur-
gency [28, 29]. However, there were no data regarding the
chief complaint in previous clinical trials of ramosetron.
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Fig. 3 Weekly changes in BSFS scores. Line graph: means ± standard deviation. P values were calculated using the χ2-test, as follows: ***P < 0.001,
**P < 0.01, and *P < 0.05
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In this study, to evaluate “clinically meaningful improve-
ments” that focus on the patient’s chief complaint, IBS-D
patients enrolled in this study were asked about their most
bothersome IBS symptoms and improvement of those
symptoms at every visit. IBS is characterized by two major
IBS symptoms, abdominal pain/discomfort and abnormal
bowel habits. Regarding the chief complaint that patients
had before administration, 34.0% of the patients in the
ramosetron 5 μg group and 42.0% of the patients in the
placebo group reported abdominal pain/discomfort. The
remaining patients complained of abnormal bowel habits,
including abnormal stool form, increased stool frequency,
defecation urgency, and a feeling of incomplete evacu-
ation. Of these, the highest proportions were related to
stool form (19.1% in ramosetron 5 μg group and 18.0% in
placebo group) and stool frequency (25.5, 20.0%, respect-
ively). Stool form and stool frequency were thus consid-
ered to be the most important chief complaints among
the bowel habit abnormalities. When compared to pla-
cebo, the greatest improvement in symptoms of the chief
complaint that patients had before administration of
ramosetron 5 μg group was shown in stool consistency.
This result was consistent with the finding that BSFS
scores were significantly lower in the ramosetron 5 μg
group than in the placebo group.
We therefore found that ramosetron acted most effect-
ively on stool consistency. Stool consistency correlates
with colonic transit time [30] and can be a good
indicator of bowel function. In rats, ramosetron also
clearly reduced stress-induced diarrhea and accelerated
defecation caused by corticotropin-releasing hormone
[14, 15]. To show how ramosetron is effective for indi-
vidual IBS symptoms, focusing on stool consistency was
considered to be acceptable in light of the drug’s
pharmacological mechanism. However, if the effect of
ramosetron on stool consistency is excessive, it leads to
constipation. In developing agents to treat IBS-D, it is
insufficient to only compare the change in stool form
from baseline between ramosetron and placebo. It was
considered important to define a clinically meaningful
improvement in stool consistency as well. BSFS scores of
3 to 5 are recognized as normal stool form in the Rome
III criteria. Therefore, patients with weekly mean BSFS
scores of 3 to 5 during one week of the treatment period
and a decrease of one or more points in mean BSFS
scores from the baseline period were defined as weekly











































Placebo (N=37) Ramosetron 5 µg (N=42)
Fig. 4 Monthly responder rates for improvement in stool
consistency. Height: responder rate (%). Error bar: 95% CI. P values
were calculated using the χ2-test as follows: ***P < 0.001, **P < 0.01,
and *P < 0.05
Fig. 5 Relationship between improvement in chief compliant and global assessment. Improvement in chief compliant that patients had before
administration was compared between responders and non-responders for global assessment of relief of overall IBS symptoms
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least two of four weeks in one month were defined as
monthly responders. We thus defined monthly re-
sponder rates in respect to improvement in stool
consistency and revealed greater responder rates in the
ramosetron 5 μg group compared to placebo group
(40.5% vs 18.9% at the last point, P = 0.067), by ad hoc
analysis. Then, we conducted a randomized, placebo-
controlled study from October 2010 to August 2011
with male IBS-D patients to evaluate the prospective ef-
fect of ramosetron with the improvement of stool
consistency as the primary endpoint. A statistically
significant improvement in stool consistency was
shown in the ramosetron group compared to the pla-
cebo group [26].
Because IBS is a syndrome that includes multiple
lower gastrointestinal symptoms, it is not known
whether patients are satisfied by an improvement in just
one universal symptom. As a result, it is considered to
be important to assess the improvement of overall IBS
symptoms using global assessment during a clinical
study of ramosetron. Moreover, the result that global
assessment was correlated with improvement in the
Japanese version IBS severity index suggests that global
assessments reflect improvement of symptom severity in
patients with IBS-D [24]. In a phase III study involving
female IBS-D patients, the co-primary endpoints of
monthly responder rate for global assessment of relief of
overall IBS symptoms and improvement in stool
consistency were used to evaluate the efficacy of ramose-
tron. The results showed that efficacy in the ramosetron
group was significantly superior to that in the placebo
group for both primary endpoints [20]. BSFS scores were
also significantly lower in the ramosetron 2.5 μg group
than in the placebo group.
Although it was unclear that an improvement of one
chief complaint influenced the other IBS symptoms of
patients, our results suggest that improvement in the
chief complaint the patient had before administration
was more frequent in the responder group in global as-
sessment compared to the non-responder group. Im-
provement of each IBS symptom seems to be related to
improvement of overall symptoms. These relationships
were obtained not only for stool form, but also for ab-
dominal pain/discomfort and stool frequency. In another
study with larger patient numbers, ramosetron showed a
statistically significant improvement in the severity of
abdominal pain/discomfort and stool frequency com-
pared to placebo at some evaluation points [20, 26].
Ramosetron was suggested to improve abdominal pain/
discomfort and stool frequency as well. Stress is consid-
ered to induce abnormal GI motility via efferent nerves,
which in turn worsens the stress response by stimulating
afferent nerves resulting visceral hypersensitivity. An-
other clinical trial with ramosetron showed that overall
scores, dysphoria, interference with activity, and food
avoidance included in IBS-QOL, disease specific health-
related QOL were significantly improved by ramosetron
treatment (5 μg for male and 2.5 μg for female) com-
pared to placebo [20, 26]. Thus, ramosetron is likely to
induce a clinical improvement in the stress-related dis-
turbance of brain-gut interactions by reducing exagger-
ated pain sensitivity and colonic motility in the gut.
The Japanese Society of Gastroenterology developed
evidence-based diagnostic and therapeutic algorithms
for the Japanese IBS guidelines [31]. In their report, 5-
HT3 antagonists should be used for IBS-D at step 1
therapy. Step 2 therapy begins by evaluating the role of
psychosocial stress on each IBS patient. Almost all of the
sites in this study were primary care sites two patients
had current evidence of anxiety neurosis and no patients
had depression. This number of patients was within our
expectations, and the severity of the anxiety was not se-
vere. In the United Kingdom, 58% of the patients with
IBS are diagnosed by general practitioners, with up to
29% of the patients referred to a specialist when primary
care management proves to be difficult or ineffective
[32]. Koloski et al. reported that the central nervous sys-
tem and gut interact bidirectionally in functional gastro-
intestinal disorders, including IBS and functional
dyspepsia [33]. Ramosetron 5 μg for male patients with
IBS-D showed significant improvement compared to
placebo in weekly responders for global assessment of
relief of overall IBS symptoms and improvement in stool
consistency at week one, with the improvement sus-
tained throughout the treatment period [26]. The same
results were shown for ramosetron 2.5 μg for female





All adverse events 20 (39.2%) 27 (57.4%)
Gastrointestinal disorders 8 (15.7%) 13 (27.7%)
Abdominal discomfort 0 (0.0%) 2 (4.3%)
Constipation 2 (3.9%) 0 (0.0%)
Hard stool 3 (5.9%) 9 (19.1%)
Nausea 2 (3.9%) 0 (0.0%)
Infections and infestations 4 (7.8%) 5 (10.6%)
Nasopharyngitis 4 (7.8%) 3 (6.4%)
Gastroenteritis 0 (0.0%) 2 (4.3%)
Hepatobiliary disorders 2 (3.9%) 2 (4.3%)
Hepatic function abnormal 2 (3.9%) 1 (2.1%)
Skin and subcutaneous tissue disorder
disorders
2 (3.9%) 3 (6.4%)
Dermatitis contact 1 (2.0%) 2 (4.3%)
Data are expressed as number (%). Events with an incidence of ≥ 3% in any of
the groups are listed
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patients with IBS-D [20]. It is considered to be import-
ant to improve gastrointestinal disorders before the
symptoms of patients move to Step 2 therapy. Those pa-
tients who have moderate severity with anxiety and/or
depression are not expected to response to gut targeted
pharmacotherapy.
Ramosetron improved stool consistency, but also occa-
sionally triggered constipation and hard stool. Actually,
the incidence of hard stool in the ramosetron 5 μg group
(9/47, 19.1%) was higher than that of the placebo group
(3/51, 5.9%) in this study. These adverse events were also
observed, with a statistically significant difference be-
tween ramosetron and placebo in a study with a larger
sample. The incidence of hard stool was 12/147 (8.2%) in
the ramosetron 5 μg group and 2/149 (1.3%, P = 0.006) in
the placebo group for male patients [26]. Additionally,
for female patients the incidences of constipation and
hard stool were significantly higher in the ramosetron
2.5 μg group (32/292, 11.0 and 66/292, 22.6%, respect-
ively) than in the placebo group (13/284, 4.6%, P = 0.005;
and 16/284, 5.6%, P < 0.001, respectively) [20]. These
were considered to be caused by the pharmacological ac-
tion of ramosetron.
This post marketing study was a pilot study and
has some limitations. First, the chief complaint was
obtained at an interview and recorded by the investi-
gator. No patients replied about symptoms other than
those that were pre-listed. Bloating has recently been
reported to be the most troublesome symptom in IBS
patients [6, 34]. In previous studies of alosetron con-
ducted in patients with IBS-D, about 10% of the pa-
tients reported bloating as their most bothersome IBS
symptom [28, 29]. However, bloating was not cap-
tured as a chief complaint on eliciting symptoms in
this study. Second, the population of this study was
limited to male patients.
The United States Food and Drug Administration
(FDA) proposed a study design for clinical trials focused
on IBS that would assist the pharmaceutical industry
and investigators who are developing drugs [35]. These
guidelines suggest the use of abdominal pain and stool
consistency as co-primary endpoints for IBS-D. They
also recommend the development of multi-item patient-
reported outcome (PRO) instruments that can capture
clinically important signs and symptoms of the IBS tar-
get population (e.g., IBS-C or IBS-D). Some PRO mea-
surements are under construction in the study of IBS
[27, 36] in accordance with FDA guidance for PRO [37].
In its PRO guidance, FDA recommends that acceptable
PRO must be couched in an explicit and evidence based
conceptual framework. In the future, PRO measure-
ments that include validated assessment of multiple
chief complaints might be available in clinical trials re-
lated to IBS.
Conclusion
Ramosetron acted most effectively on stool consistency.
Improvement in stool consistency is considered to be a
clinically meaningful endpoint in showing how ramose-
tron was effective for individual IBS symptoms. We
found that the monthly responder rate for improvement
in stool consistency can be used as a co-primary end-
point, together with global assessment.
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